Research ArticleTechnology/Application

Statistical Quality and Process Control in Biopharmaceutical Manufacturing—Practical Issues and Remedies

Nicolas Heigl, Bernhard Schmelzer, Franz Innerbichler and Mahesh Shivhare
PDA Journal of Pharmaceutical Science and Technology September 2021, 75 (5) 425-444; DOI: https://doi.org/10.5731/pdajpst.2020.011676

References

  1. 1.↵
    1. Shewhart W. A.,
    2. Deming W. E.
    Statistical Method from the Viewpoint of Quality Control, 1st ed.; Dover Publications: Mineola, New York, 1986.
  2. 2.↵
    1. Shewhart W. A.
    Economic Control of Quality of Manufactured Product, 1st ed.; Martino Fine Books: Eastford, CT, 2015.
  3. 3.↵
    1. Deming W. E.
    Out of the Crisis, 1st ed.; MIT Press: Cambridge, MA, 1982; Vol. 1.
  4. 4.↵
    1. Box G. E. P.,
    2. Luceno A.,
    3. Paniagua-Quinones M.
    Statistical Control by Monitoring and Adjustment, 2nd ed.; Wiley: Hoboken, NJ, 2009.
  5. 5.↵
    1. Montgomery D. C.
    Introduction to Statistical Quality Control, 6th ed.; John Wiley: New York, 2008.
  6. 6.↵
    1. Wheeler D. J.,
    2. Chambers D. S.
    Understanding Statistical Process Control, 2nd ed.; SPC Press: Knoxville, TN, 1992.
  7. 7.↵
    1. Wheeler D. J.
    Advanced Topics in Statistical Process Control, 1st ed.; SPC Press: Knoxville, TN, 1995.
  8. 8.↵
    1. Wheeler D. J.
    Guide to Data Analysis, 1st ed.; SPC Press, Knoxville, TN, 2005.
  9. 9.↵
    1. Grant E. L.,
    2. Leavenworth R. S.
    Statistical Quality Control, 7th ed.; McGraw-Hill Book Co: Singapore, 1999.
  10. 10.↵
    U.S. Food and Drug Administration. Guidance for Industry: (Q8 (R2)) Pharmaceutical Developments; U.S. Food and Drug Administration: Rockville, MD, 2009.
  11. 11.↵
    U.S. Food and Drug Administration. ORA Laboratory Manual—Section 4: Laboratory Applications of Statistical Concepts; U.S. Food and Drug Administration: Rockville, MD, 2013.
  12. 12.↵
    U.S. Food and Drug Administration. Guidance for Industry: (ICH Q-10) Quality Systems Approach to Pharmaceuticals Cgmp Regulations; U.S. Food and Drug Administration: Rockville, MD, 2006.
  13. 13.↵
    U.S. Food and Drug Administration. Guidance for Industry: Part 11, Electronic Records; Electronic Signatures—Scope and Application; U.S. Food and Drug Administration: Rockville, MD, 2003.
  14. 14.↵
    U.S. Food and Drug Administration. Guidance for Industry: Process Validation: General Principles and Practices; U.S. Food and Drug Administration: Rockville, MD, 2011.
  15. 15.↵
    U.S. Food and Drug Administration. Guidance for Industry: Submission of Quality Metrics Data; U.S. Food and Drug Administration: Rockville, MD, 2016.
  16. 16.↵
    U.S. Food and Drug Administration. Topic 2—Stage 3 Process Validation: Applying Continued Process Verification Expectations to New and Existing Products. International Society for Pharmaceutical Engineering; online discussion paper, 2012.
  17. 17.↵
    Parenteral Drug Association. A-Mab: A Case Study in Bioprocess Development; Parenteral Drug Association: Bethesda, MD, 2009.
  18. 18.↵
    Parenteral Drug Association. Utilization of Statistical Methods for Production Monitoring; Parenteral Drug Association: Bethesda, MD, 2012, 59.
  19. 19.↵
    Parenteral Drug Association. Process Validation: A Lifecycle Approach; Parenteral Drug Association: Bethesda, MD, 2013, 60.
  20. 20.↵
    BioPhorum Operations Group. Continued Process Verification: An Industry Position Paper with Example Plan; BioPhorum Operations Group: Sheffield, UK, 2014, Vol. 1.
  21. 21.↵
    International Society for Pharmaceutical Engineering. Product Quality Lifecycle Implementation (PQLI)—SPC and Process Monitoring; International Society for Pharmaceutical Engineering, Online Discussion Paper, 2008.
  22. 22.↵
    ASTM International. Standard E2587-12: Standard Practice for Use of Control Charts in Statistical Process Control; ASTM International: West Conshohocken, PA, 2012.
  23. 23.↵
    ASTM International. Standard E29-13: Standard Practice for Using Significant Digits in Test Data to Determine Conformance with Specifications; ASTM International: West Conshohocken, PA, 2013.
  24. 24.↵
    1. Morrow T.,
    2. Felcone L. H.
    Defining the Difference: What Makes Biologics Unique. Biotechnol. Healthcare 2004, 1, 24–29.
    OpenUrl
  25. 25.↵
    1. Wheeler D. J.
    Normality and the Process Behavior Chart, 1st ed.; SPC Press, Knoxville, TN, 2000.
  26. 26.↵
    1. Nelson L. S.
    The Shewhart Control Chart—Tests for Special Causes. J. Qual. Technol. 1984, 16, 237–239.
    OpenUrlWeb of Science
  27. 27.↵
    R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2018.
  28. 28.↵
    1. Wickham H.
    Ggplot2: Elegant Graphics for Data Analysis, 2nd ed.; Springer Verlag: New York, 2016.
  29. 29.↵
    1. Bisgaard S.,
    2. Kulahci M.
    Quality Quandaries: The Effect of Autocorrelation on Statistical Process Control Procedures. Quality Engineering 2005, 17, 481–489.
    OpenUrl
  30. 30.↵
    NIST/Sematech. E-Handbook of Statistical Methods. http://www.itl.nist.gov/div898/handbook/
  31. 31.↵
    1. Persson T.,
    2. Rootzen H.
    Simple and Highly Efficient Estimators for a Type I Censored Normal Sample. Biometrika 1977, 64, 123–128.
    OpenUrlCrossRefWeb of Science
  32. 32.↵
    1. Haas C. N.,
    2. Scheff P. A.
    Estimation of Averages in Truncated Samples. Environ. Sci. Technol. 1990, 24, 912–919.
    OpenUrlCrossRefWeb of Science
  33. 33.↵
    1. Plutta P. L.
    FDA Lifecycle Approach to Process Validation—What, Why, and How? J. Validation Technol. 2011, 17, 51–61.
    OpenUrl
  34. 34.↵
    1. Boyer M.,
    2. Gampfer J.,
    3. Zamamiri A.,
    4. Payne R.
    A Roadmap for the Implementation of Continued Process Verification. PDA J. Pharm. Sci. Technol. 2016, 70, 282–292.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Parkesh V.,
    2. Rajoria R.,
    3. Kumar D.
    Statistical Process Control. Int. J. Res. Engineer. Technol. 2013, 2, 70–72.
    OpenUrl
  36. 36.↵
    1. Khlebnikova E.
    Statistical Tools for Process Qualification. J. Validation Technol. 2012, 18, 60–66.
    OpenUrl
  37. 37.↵
    1. Torbeck L. D.
    OOS, OOT, OOC, OOSC, Pharm. Technol., 2011, 35 (October).
  38. 38.↵
    1. Wheeler D. J.
    Probability Models Do Not Generate Your Data. Quality Digest Daily, manuscript no. 194, 2009a.
  39. 39.↵
    1. Wheeler D. J.
    Do You Have Leptokurtophobia? Quality Digest Daily, manuscript no. 200, 2009b.
  40. 40.↵
    1. Wheeler D. J.
    Are You Sure We Don't Need Normally Distributed Data. Quality Digest Daily, manuscript no. 220, 2010.
  41. 41.↵
    1. Wheeler D. J.
    Myths About Process Behavior Charts. Quality Digest Daily, manuscript no. 232, 2011.
  42. 42.↵
    1. Wheeler D. J.
    Contra Two Sigma; the Consequences of Using Wrong Limits. Quality Digest Daily, 2013a.
  43. 43.↵
    1. Wheeler D. J.
    The Problems of Long Term Capability. Quality Digest Daily, manuscript no. 257, 2013b.
  44. 44.↵
    1. Wheeler D. J.
    History of the Chart for Individual Values. Quality Digest Daily, 2017.
  45. 45.↵
    1. Woodall W. H.
    Controversies and Contradictions in Statistical Process Control. J. Qual. Technol. 2000, 32, 341–350.
    OpenUrl
  46. 46.↵
    1. Hindle S. A.
    Process Capability: How Many Data? Quality Digest Daily, 2015
  47. 47.↵
    1. Yang H.,
    2. Zhao W.,
    3. O'Day T.,
    4. Fleming W.
    Environmental Monitoring: Setting Alert and Action Limits Based on a Zero-Inflated Model. PDA J. Pharm. Sci. Technol. 2013, 67, 2–8.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Yau K. K. W.,
    2. Lee A. H.,
    3. Wang K.
    Zero-Inflated Negative Binomial Mixed Regression Modeling of Over-Dispersed Count Data with Extra Zeros. Biom. J. 2003, 45, 437–452.
    OpenUrlCrossRefWeb of Science
  49. 49.↵
    1. Ridout M.,
    2. Demetrio C. G. B.,
    3. Hinde J.
    A Score Test for Testing a Zero-Inflated Poisson Regression Model against Zero-Inflated Negative Binomial Alternatives. Biometric 2001, 57, 219–223.
    OpenUrl
  50. 50.↵
    1. Armbruster D. A.,
    2. Pry T.
    Limit of Blank, Limit of Detection and Limit of Quantitation. Clin. Biochem. Rev. 2008, 29, 49–52.
    OpenUrl
  51. 51.↵
    1. Rathore A. S.,
    2. Undey C.,
    3. Konold P.
    Monitoring of Biopharmaceutical Processes: Present and Future Approaches. BioPharm Int. 2009, 22.
  52. 52.↵
    1. Macgregor J. F.
    A Different View of the Funnel Experiment. J. Qual. Technol. 1990, 22, 255–259.
    OpenUrl
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Statistical Quality and Process Control in Biopharmaceutical Manufacturing—Practical Issues and Remedies
Nicolas Heigl, Bernhard Schmelzer, Franz Innerbichler, Mahesh Shivhare
PDA Journal of Pharmaceutical Science and Technology Sep 2021, 75 (5) 425-444; DOI: 10.5731/pdajpst.2020.011676
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords